Treatment of relapsed and refractory aggressive non-Hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE

Aurer, Igor; Mitrović, Zdravko; Nemet, Damir; Radman-Livaja, Ivo; Sertić, Dubravka; Serventi-Seiwerth, Ranka; Štern-Padovan, Ranka; Šantek, Fedor; Nola, Marin; Mrsić, Mirando; Labar, Boris

Pregled bibliografske jedinice broj: 395153

Treatment of relapsed and refractory aggressive non-Hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE

Aurer, Igor; Mitrović, Zdravko; Nemet, Damir; Radman-Livaja, Ivo; Sertić, Dubravka; Serventi-Seiwerth, Ranka; Štern-Padovan, Ranka; Šantek, Fedor; Nola, Marin; Mrsić, Mirando; Labar, Boris

Treatment of relapsed and refractory aggressive non-Hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE // Journal of Chemotherapy, 20 (2008), 5; 640-644 (recenziran, članak, stručni)

CROSBI ID: 395153 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Treatment of relapsed and refractory aggressive non-Hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE

Autori
Aurer, Igor ; Mitrović, Zdravko ; Nemet, Damir ; Radman-Livaja, Ivo ; Sertić, Dubravka ; Serventi-Seiwerth, Ranka ; Štern-Padovan, Ranka ; Šantek, Fedor ; Nola, Marin ; Mrsić, Mirando ; Labar, Boris

Izvornik
Journal of Chemotherapy (1120-009X) 20 (2008), 5; 640-644

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
Lymphoma non-Hodgkin; Lymphoma B-cell; Lymphoma diffuse; Lymphoma large-cell; Lymphoma T-cell; Ifosfamide; Methotrexate; Etoposide; Carboplatinum

Sažetak
We report the outcomes of 45 patients with relapsed or refractory aggressive NHL treated with a combination of ifosfamide, carboplatinum and etopoisde (ICE) and 28 patients treated with a combination of ifosfamide, methotrexate and etoposide (IMVP) during two 5-year periods. The response rate (RR) to ICE was 47%, 2-year overall survival (OS) 31% and 2-year event-free survival (EFS) 22%. These results were similar to those obtained with IMVP (RR 39%, 2-year OS 23%, 2-year EFS 13% ; p=0, 355 for RR, 0, 275 for OS, 0, 668 for EFS). Higher IPI scores and refractoriness to treatment were negative prognostic factors, immunophenotype (B vs. T) had no influence on prognosis. Changing from IMVP to ICE, does not substantially improve outcomes of patients with relapsed or refractory aggressive NHL. Patients with relapsed/refractory aggressive B-NHL do not have a superior outcome in comparison to those with T-NHL if treated with chemotherapy alone

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA

Projekti:
108-0000000-3426 - CD 43 - prognostički biljeg za predviđanje ishoda oboljelih od limfoma (Ilić, Ivana, MZOS ) ( CroRIS)
108-1081872-1908 - Dijagnostika i liječenje limfoma (Aurer, Igor, MZOS ) ( CroRIS)
108-1081872-1913 - LEUKEMIJE I TRANSPLANTACIJA KRVOTVORNIH MATIČNIH STANICA (Duraković, Nadira, MZOS ) ( CroRIS)
108-1081872-2061 - LIMFOPROLIFERATIVNE BOLESTI I TRANSPLANTACIJA KRVOTVORNIH MATIČNIH STANICA (Nemet, Damir, MZOS ) ( CroRIS)